Immunologic Host Defense in Melanoma: Delineation of Effector Mechanisms Involved and of Strategies for the Augmentation of Their Efficacy  by Schneeberger, Achim et al.
Immunologic Host Defense in Melanoma: 
Delineation of Effector Mechanisms Involved and of 
Strategies for the Augmentation of Their Efficacy 
Achim Schneeberger, Frieder Koszik, and Georg Stingl 
Division ofIrnmunology, Allergy, and Infectious Diseases , Department of Dermatology, University of Vienna Medical School, 
Vienna, Austria 
There exists substantial evidence that the immune 
system plays an important role in the prevention and 
control of cancer. This evidence includes 1) the oc­
casional clinical observation of spontaneous tumor 
regression. 2) the correlation of this phenomenon 
with the presence of tumor-infiltrating lymphocytes. 
and 3) the in vitro demonstration of the specificity of 
tumor-infiltrating lymphocytes for the autologous 
tumor. Because of the only weak immunogenicity of 
and the occurrence of active immunosuppression by 
the cancer. this response often does not suffice to 
combat the neoplasm successfully. One strategy for 
amplifying the anti-tumor immune response is vac­
cination of patients or experimental animals with 
cancer cells. the immunogenicity of which has been 
enhanced by the introduction of genes encoding 
immunostimulatory molecules. Several investigators 
have shown that transfection of certain types of 
cancer cells with the interleukin-2 gene reduces their 
EVIDENCE FOR THE EXISTENCE OF A TUMOR-SPECIFIC 
IMMUNE RESPONSE IN PATIENTS WITH MELANOMA 
Many clinical observations suggest an interaction between the 
host's immune system and melanoma. These include the occur­
rence of spontaneous melanoma regression; the induction of a 
melanocytodestructive process as evidenced by the development of 
halo nevi, uveitis, and/or vitiligo; and a prolonged latency period 
between removal of the primary tumor and the appearance of 
metastases in some patients. These observed tumor-suppressive or 
even tumoricidal phenomena point to the existence of specific 
anti-tumor effector mechanisms. 
In the case of melanoma, histopathologic analysis of primary and, 
to a lesser extent, metastatic lesions reveals the presence of 
leukocytes surrounding and infiltrating tumor cell nests. Compar­
ison of the intensity of the inflanunatory infiltrate at different stages 
of the disease shows that superficial spreading melanomas are more 
densely infiltrated by CD45 + leukocytes than are nodular melano­
mas (three times less) or even melanoma metastases (seven to eight 
times less) [1,2]. Typically, the majority (approximately SO%) of 
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tumorigenicity and that immunization with interleu­
kin-2-transduced cancer cells protects animals &om 
challenge with a tumorigenic dose of wild-type can­
cer cells. We have recently established a murine 
melanoma model (M-3) and have used it to elucidate 
the mechanism by which interleukin-2-transfected 
cancer cells can induce protective immunity. We will 
demonstrate the following: 1) that the mechanisms 
leading to the loss of tumorigenicity of interleukin-
2- expressing cancer c�lls are somewhat different 
from those leading to the rejection of wild-type 
cancer cells in immunized animals. 2) that immunity 
resides within both CD4- and CDS-positive T cells, 
and 3) that host antigen-presenting cells are probably 
important in the induction of this protective anti­
tumor immunity. Key wovds: immunothevapylintevleukin­
Zltumov-injiltvating lymphocytes. J Invest Devmatol 105: 
110S-116S, 1995 
infiltrating leukocytes consist of CD3 +TcRa/ {3+ lymphocytes be­
longing predominantly to the CD4 + subset. The ratio between 
CD4+ and CDS+ T cells is dependent on the type of lesion 
investigated. In early disease stages (superficial spreading melanoma 
less than 0.75 mm) , there are approximately four times more CD4 + 
T cells detectable than CDS+ cells (T4/TS = 3.7). In advanced 
lesions, characterized by a pronounced vertical growth pattern of 
the cancer cells, an almost equal ratio between CD4 + and CDS + T 
cells is usually found (T4/TS = 1.3). Most of the infiltrating T cells 
exhibit the CD45RO memory phenotype [2], and in cutaneous but 
not extracutaneous melanoma lesions, approximately 50% of the T 
cells are positive for the cutaneous lymphocyte antigen as defined 
by reactivity with the monoclonal antibody HECA-452 [2]. Studies 
investigating the expression of T-cell activation markers have 
revealed that most of the tumor-infiltrating lymphocytes (TIL) 
express human leukocyte antigen (HLA)-DR [1,3,4], and some 
display interleukin-2 (IL-2) and transferrin receptors. 
Infiltrating leukocytes other than T cells are almost exclusively 
major histocompatibility complex (MHC) class II-bearing antigen­
presenting cells (APC), i.e., macrophages and Langerhans cells [1]. 
B cells and natural killer cells are either absent or present only 
infrequently in melanoma lesions. 
Several arguments exist for a critical role of TIL in the clinically 
relevant anti-melanoma immune response. These include 1) the 
finding that the magnitude of the cellular infiltrate correlates with 
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the occurrence of clinical and histopathologic signs of tumor 
regression [4], 2) the observation of close contact between TIL and 
(living and dying) melanoma cells [5], 3) the demonstration of 
T-cell receptor oligoclonality in TIL [4,6-9] and, finally, 4) the 
demonstration that lymphocytes isolated from melanoma lesions 
[10,11], from tUmor-draining lymph nodes, and from peripheral 
blood [12] of melanoma patients can be propagated and induced to 
lyse the autologous melanoma cells in an MHC class I-restricted 
fashion. 
The availability of such tumor-specific, HLA-restricted T-cell 
clones formed the basis for the identification and molecular char­
acterization of tumor antigens. In principle, two strategies have 
been followed. The first one is based on genetic methods. Libraries 
of eDNA were prepared from tumor cells, and molecular clones 
from these libraries were transfected into HLA-matched target 
cells. These were then screened for the presence of the antigenic 
epitope recognized by the tumor-specific T-cell clones derived 
from the same or other (HLA-matched) patients (reviewed in [13]). 
The second strategy takes advantage of the observation that acid 
treatment of MHC class I molecules releases the peptides bound to 
them [14]. Pep tides eluted from MHC molecules of tumor cells 
were separated based on their biochemical features and then added 
to MHC-matched target cells, which sensitizes them for recogni­
tion by the relevant cytotoxic T cell [15]. Most of the so far 
identified melanoma antigens, as defined by the patient's T-cell 
clones, are melanocyte differentiation antigens. The others are 
derived from genes that are silent in most or all normal cells but 
expressed in cancer cells. Using the eDNA transfection strategy, 
van der Bruggen et al [16] were the first to isolate a gene (melanoma 
antigen-l, MAGE-1) coding for an MHC class I-restricted tumor 
antigen on human tumor cells. MAGE-l belongs to a family of 12 
closely related genes and is expressed in 20% to 40% of human 
cancers, including melanomas. Among normal tissues, it has only 
been fourid in testis [17]. The sequence of this gene is not related to 
any known gene, and the function(s) of MAGE-l, as well as those 
of the other 11 members of the MAGE family, remain to be 
elucidated. The antigenic epitopes encoded by MAGE-l are usually 
recognized in the context of HLA-Al or HLA-C molecules 
[16,18]. 
In contrast to MAGE-l, the tyrosinase gene gives rise to anti­
genic determinants that can be recognized by both CD8+ MHC 
I-restricted cytotoxic T cells [19] and CD4 + MHC II-restricted 
T-Iymphocyte clones [20]. This feature of the tyrosinase molecule 
may be advantageous with regard to its use in active immunother­
apy. The relevance of differentiation antigens for protective anti­
tumor immunity is evidenced by the therapeutic effect of adoptively 
transferred gpl00/Mel-17-specific TIL. The corresponding protein 
[15,21] is present in melanin-producing cells and constitutes the 
target of the monoclonal antibody HMB45. It is important that 
antigenic determinants derived from the gpl00 protein can be 
recognized by cytotoxic T lymphocytes (CTL) from multiple 
(HLA-matched) melanoma patients. This could also be shown for 
another melanocyte differentiation antigen called MART-l/Melan 
A [22,23], the function of which is still uriknown. 
The view that tissue-specific antigens contribute to the actual 
anti-tumor reactivity of the host immune system is further strength­
ened by the clinical observation that the appearance of vitiligo in 
some melanoma patients, occurring either spontaneously or during 
immunotherapy, is associated with an improved prognosis [24]. 
IL-2 AND PASSIVE IM MUNOTHERAPY 
These data indicated that the immune system of melanoma patients 
is theoretically capable of mounting an effective anti-tumor im­
mune response. Unfortunately, this response is not fully developed 
in many patients and thus does not suffice to eradicate the neo­
plasm. On the one hand, the ongoing immune response per se could 
be too weak to be effective; alternatively, the tumor itself could 
counteract the host's anti-cancer immune reaction by actively 
suppressing or silencing tumor-reactive T lymphocytes [25-27]. As 
a consequence, amplification of the already established anti-cancer 
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immune effector mechanisms or elicitation of others can be ex­
pected to tip the balance between tumor-induced immunosuppres­
sion and tumor-antigen-driven inununostimulation toward a more 
powerful and, perhaps, even protective immune response. 
One obvious strategy to accomplish this goal is the use of inununo­
modulatory cytokines. IL-2, originally named T-cell growth factor 
[28], was one of the first immunostimulatory molecules investi­
gated. Its availability in recombinant form led various investigators 
to use systemic IL-2 immunotherapy for the treatment of humans 
(and experimental animals) with advanced melanoma [29]. Despite 
impressive remissions in animals, the overall response rate in man 
ranged between 10% and 35% and, thus, was not clearly superior to 
established chemotherapeutic regimens [30,31]. As an extension of 
this approach, investigators [30,32] used high-dose human IL-2 in 
combination with so-called lymphokine-activated killer cells. 
These cells, generated by ex vivo incubation of peripheral blood 
lymphocytes with IL-2, are capable of lysing tumor cells in an 
antigen-nonspecific, non-MHC-restricted fashion. [33]. Although 
initial results with this therapeutic modality in patients with ad­
vanced cancer were encouraging [34], it now appears that the 
addition of lymphokine-activated killer cells does not significandy 
enhance the anti-melanoma activity of IL-2 [35]. Anti-melanoma 
responses better than those obtained with IL-2+1- lymphokine­
activated killer cells were seen when T lymphocytes were derived 
from the tumor itself (TIL), expanded ex vivo with human IL-2, and 
then administered to the patients together with human IL-2 
[36,37]. The ultimate limitation of these recombinant human 
IL-2-based immunotherapies is imposed by the systemic toxicity of 
high-dose recombinant human IL-2, primarily. by the IL-2-induced 
capillary leak syndrome resulting in excessive fluid extravasation, 
hypotension, and organ dysfunction (e.g., oliguria) [38]. FUrther­
more, outgrowth of certain T-cell clones during long-term ex vivo 
expansion of TIL [6,7,11] reduces the repertoire of epitopes 
recognized by those selected T-cell populations and thus precludes 
a possible cooperation between different T-cell clones and subsets 
during destruction of the neoplasm. 
DEVELOPMENT OF CANCER VACCINES 
An immunotherapeutic alternative to the direct cytokine-driven 
expansion of effector cell populations is the vaccination of patients 
or experimental animals with inactivated or modified cancer cells. 
The modifications are aimed at augmenting the immunogenicity of 
the tumor cells, and, as a consequence, these vaccines should be 
able to induce new effector cells or enhance the ongoing anti-tumor 
immune response. Xenogenization of cancer cells, i.e., the expres­
sion of highly antigenic foreign proteins (e.g., histocompatibility 
antigens, viral proteins), was one of the strategies proposed to 
enhance their immunogenicity. Initially, this was accomplished by 
superinfecting cancer cells with nonpathogenic oncolytic viruses 
(e.g., vaccinia virus, Newcastle disease virus, vesicular stomatitis 
virus). The immune response against the viral antigens associated 
with the tumor cell membrane is believed to provide helper activity 
for antibody and T-cell responses to the adjacent tumor antigens 
[39-41]. Because most of the clinical trials conducted to date have 
used historic co�trols [42-44], the efficacy of this treatment 
modality remains to be determined. 
As an outgrowth of these studies, several groups of investigators 
have successfully used gene transfer techniques to express immu­
nogenic foreign molecules in cancer cells. Fearon et al [45] trans­
fected cancer cells with the gene coding for the hemagglutinin 
antigen of infiuenza virus and showed that immunization with these 
hemagglutinin-antigen-transfected cancer cells conferred ctoss­
protective immunity against a challenge with nontransfected paren­
tal cancer cells. 
In 1990, two groups of investigators independendy reported that 
the expression of the IL-2 gene in cancer cells abrogates their 
tumorigenicity upon subcutaneous injection into syngeneic, euthy­
mic animals [46,47]. They further observed that injection of 
IL-2-transfected tumor cells protected the animals against a subse­
quent challenge with the parental, but not with histogenetically 
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unrelated, tumor cells [46,47]. The data originally presented by 
Fearon et al [46] and Gansbacher et al [47] suggested that the tumor 
cells themselves interact with the T cells and that IL-2 acts by 
bypassing the helper T-cell function in the generation of tumor­
specific cytotoxic T cells. This concept was further strengthened by 
the finding that cancer cells expressing the costimulatory molecule 
B7 could be used to induce a protective anti-tumor immune 
response (reviewed in [48)). 
This concept of helper-independent tumor antigen presentation 
by the cancer cell itself was later questioned when it was found that 
the protective effect of vaccination with genetically modified cancer 
cells could be accomplished not only by transfecting the cancer cells 
with genes encoding typical T-cell growth-promoting cytokines 
(e.g., IL-2 [46,47], IL-4 [49], IL-7 [50)), but also when cytokines 
were expressed in cancer cells that do not act primarily at the T-cell 
level (e.g., granulocyte-macrophage colony-stimulating factor 
[51], IL-6 [52], interferon-y [53)). The protective effect of cyto­
kine-based cancer vaccines depended not only on the type and 
amount [49,54] of cytokine produced but also differed with the 
anDnal model of cancer investigated. For example, IL-2, while 
effective in certain tumor models (CT26, colon carcinoma [46]; 
CMS5, fibrosarcoma [47]; P815, mastocytoma [55]), was less 
effective or even ineffective in others (B16, melanoma [46,51)). 
Similar observations were made with IL-4 [49,51] and IFN-y 
[51,53]. To understand the cellular and molecular events that lead 
to the rejection of IL-2-transfected cancer cells and to the gener­
ation of a protective anti-tumor immune response, we recently 
established a murine melanoma model. 
Description of the M-3 Melanoma Model The M-3 tumor 
cell line is derived from the Cloudman S91 melanoma, which arose 
spontaneously in a DBA/2 mouse [56]. Phenotypically, M-3 cells 
constitutively express low levels of MHC class I antigens, CD44, 
and CD54 but are devoid of MHC class II antigens, B7-1/2, and 
heat-stable antigen [57]. Tumorigenicity studies have revealed that 
the subcutaneous inoculation of 3 X 103 wild-type M-3 cells into 
syngeneic DBA/2 mice regularly leads to the appearance of pig­
mented tumors and eventually to the death of the anDnals. Tumors 
grow rapidly (5 weeks after subcutaneous application of 1 X 105 
cells, tumors may reach a size of 1.5 X 1.5 X 1.5 em) and infiltrate 
the surrounding tissue, but do not form distant metastases that are 
macroscopically visible at autopsy. 
Expression ofIL-2 in M-3 Cells Abrogates Their Tumorige­
nicity To transfect the M-3 melanoma cells with the IL-2 gene, 
we used the receptor-mediated, adenovirus-augmented transferrin­
fection technique [58], which leads to very high gene expression 
(IL-2 production rates in vitro between 30,000 and 80,000 U/I06 
M-3 cells124 h) without the need for selection procedures. Trans­
ferrinfection of M-3 cells enhances the CD54 expression of the 
transfected cells but does not influence their MHC antigen expres­
sion pattern and fails to induce anti-heat-stable antigen or anti-B7-
112 reactivity [57]. In contrast to the high tumorigenicity of 
wild-type M-3 cells, subcutaneous inoculation of IL-2'-transfected 
M-3 cells into syngeneic, euthymic DBA/2 hosts never resulted in 
tumor formation [57] (Fig IA). The possibility that IL-2 transfec­
tion acts by decreasing the intrinsic carcinogenicity of the mela­
noma cells is unlikely because of the following: 1) IL-2-transfected 
M-3 cells exhibit an in vitro growth rate similar to that of nonmodi­
fied M-3 cells (data not shown); and 2) subcutaneous inoculation of 
mock-transferrinfected M-3 cells into DBA/2 mice leads to the 
establishment of rapidly growing tumors [57] (Fig iA). Alternative 
explanations for this phenomenon are that the expression of the 
IL-2 gene in cancer cells either disturbs the ·microenvironment 
needed for the establishment of a solid tumor (cell-cell and! or 
cell-matrix interactions; neovascularization) or induces or enhances 
host anti-tumor immune reactions. The demonstration that such 
injection sites are heavily inffitrated by granulocytes and macro­
phages ([54]; Koszik, unpublished observations) or natural killer 
cells [59] rather implies that IL-2-producing cancer cells evoke 
local, tumor-destructive host defense mechanisms. This host-
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Figure 1. Lack of tumorigenicity of IL-2-expressing M-3 cells 
upon subcutaneous impiantation into both euthymic and athymic 
mice. Euthymic (A) and athymic, nude (B) mice (five mice per group) were 
injected subcutaneously with either 1 X 105 wild-type M-3 cells (M-3), 1 X 
105 mock-transfected M-3 cells (M-3-pSP), or 1 X 105 IL-2-transfected 
M-3 cells (producing 30,000 U IL-2110· cells/24 h). Animals were 
monitored for tumor growth by measuring the tumor diameters. 
driven destruction of IL-2-transfected M-3 cells could even be 
further facilitated by their erihanced expression of intercellular 
adhesion molecule-l compared with wild-type M-3 cells, allowing 
for a better contact between the infiltrating leukoCytes and the 
cancer cells. The further finding that IL-2-expressing cancer cells 
are even rejected upon subcutaneous implantation into nude, 
athYmic mice indicates that T lymphocytes are not critically needed 
for the elimination of IL-2-setreting tumor cells [59] (Fig lB). 
Immunization. With IL-2-Transfected M-3 Melanoma Cells 
Results in a State of Protective T -Cell-Mediated Tumor 
Immunity Although injection of M-3 cells, even in very low 
numbers, results in cancer formation in syngeneic recipients, M-3 
cells are apparently capable of inducing an anti-tumor immune 
response. This was evidenced by the finding that 20% to 30% of the 
anDnals that had been injected twice at a weekly interval with 
irradiated M-3 cells survived a subsequent challenge with a tumor­
igenic M-3 cell dose [57]. Similarly, two immunizations with 
mock-transfected and irradiated M-3 cells protected 20% to 30% of 
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Figure 2. Vaccination of DBAl2 mice with IL-2-transfected and 
irradiated M-3 cells protects these animals against a subsequent 
challenge with the wild-type melanoma cells but not with synge­
neic unrelated KLN carcinoma cells. DBA/2 mice (six to eight per 
group) were injected subcutaneously twice at a weekly interval with 1 X 
105 irradiated, IL-2-transfected M-3 cells (producing 30,000 U IL-21106 
cells124 h) or, for control purposes, with 1 X 105 mock-transfected and 
irradiated M-3 cells_ One group of mice was left untreated_ One week after 
the second immunization, the animals were challenged with 1 X 105 
wild-type M-3 cells or with histogenetically unrelated KLN carcinoma cells 
(1 X 105)_ Thereafter, tumor growth was monitored weekly by measuring 
the tumor diameters. The numbers represent the ratio of tumor-bearing 
animals/total animals in a given group. 
the animals against a subsequent inoculation of M-3 cells, whereas 
the remaining animals developed rapidly growing melanomas (Fig 
2). These data indicate that irradiated M-3 cells are only weakly 
immunogenic and that transferrinfection itself does not significantly 
enhance their immunogenicity. In sharp contrast to this situation, 
none of the animals that had been immunized twice with IL-2-
transfected M-3 cells developed a tumor after challenge with 
wild-type M-3 cells [57] (Fig 2). More important, at least from a 
clinical viewpoint, vaccination with IL-2-transfected and irradiated 
M-3 cells can lead to the elimination of preexisting (7 d) wild-type 
M-3 melanoma cell deposits [57]. 
The findings that vaccination of nude, athymic mice with 
IL-2-transfected M-3 cells cannot protect them against a challenge 
with wild-type M-3 cells [57] and that immunization of euthymic 
mice with IL-2-producing M-3 melanoma cells does not cross­
protect the animals against a challenge with syngeneic, but histo­
genetically unrelated tumor cells [57] (Fig 2) suggest that the 
protective effect of IL-2- based cancer vaccines results from the 
generation of a T-cell-dependent, antigen-specific immune re­
sponse. 
To test this assumption, we subcutaneously injected sublethally 
irradiated, naive DBA/2 mice with a mixture of cancer cells (M-3 
or KLN 205) and T -cell/T -cell-subset-enriched or T -cell-depleted 
splenocytes from M-3/IL-2-immunized or nonirnmunized animals. 
The mice were then monitored regularly for the appearance of 
cancer . The results showed that transfer ofT-ceIl-enriched, but not 
of T-cell-depleted, splenocytes from M-3/IL-2-immunized ani­
mals conferred protection against the growth of wild-type M-3 cells 
but did not protect against a challenge with unrelated KLN 205 
carcinoma cells [57]. Transfer of either CD4 + or CDS+ T lympho­
cytes from M-3/IL-2-immunized mice led to only partial protec­
tion against challenge with M-3 melanoma cells [57], indicating 
that both T-cell subsets are needed for an effective anti-tumor 
immune response. Other investigators used in vivo T-cell depletion 
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to study the role of T lymphocytes during the rejection of non­
modified cancer cells and obtained essentially the same results 
[49,51,59,60]. 
T lymphocytes from immunized animals could exert their anti­
tumor effect by directly attacking and destroying the cancer cells 
and/or by recruiting and activating other leukocytes able to kill 
tumor cells. To investigate the first possibility, we tested the 
tumor-specific CTL activity of splenocytes from immunized and 
naive animals. Results obtained showed that after coculturing 
spleen cells from immunized or from naive animals with metabol­
ically inactive M-3 cells, only the splenocytes from immunized 
animals were able to lyse the M-3 cell target in an antigen-specific, 
H-2-restricted manner [57]. Depletion experiments revealed that 
this tumor-specific lytic activity resides within the CDS+ T lym­
phocyte subset and that neither CD4 + T cells nor natural killer cells 
are able to destroy M-3 cells [57]. Together with the demonstration 
of CDS+ lymphocytes at challenge sites of immunized animals, 
these and similar findings by other investigators [46,47,59] are 
certainly compatible with the assumption that MHC class 1-
restricted cytotoxicity is a biologically relevant effector mechanism 
in IL-2-based cancer vaccine models. However, these observations 
do not necessarily mean that CDS+ CTL are the only effector cells 
operative in this system. In fact, CD4 + lymphocytes as well as 
macrophages and granulocytes (perhaps attracted and activated by 
CD4 + T -cell-derived cytokines) are abundant at the challenge sites 
of immunized animals and may well be involved in the actual 
tumor-destructive processes_ 
Mode of T-Cell Activation In accordance with earlier obser­
vations by Fearon et al [46] and Gansbacher et al [47], the generation 
of H-2-restricted CTL can be explained by a direct, i.e., helper 
T-cell-independent, activation of naive CDS+ T cells by IL-2-
transfected cancer cells (Fig 3). The critical requirement for the 
validity of this concept is the demonstration of a direct cell-to-cell 
contact between IL-2-transfected cancer cells and CDS+ T cells. 
Such an interaction could conceivably occur at the immunization 
site and/or in the draining lymph node. The virtual absence ofT 
cells at the immunization site, as observed by us and by others 
([54,59]; Koszik, unpublished observations), renders the former 
possibility quite unlikely. Concerning the alternative concept, we 
are not aware of data demonstrating conclusively that IL-2-
transfected cancer cells can actively migrate to the draining lymph 
node after subcutaneous inoculation. However, the possibility 
exists that at least some of them are able to do so. 
Our findings and those of other investigators show clearly that 
the induction of optimal protection by the IL-2- based cancer 
vaccine depends on both CDS+ and CD4+ cells [49,51,59,60]. 
Because M-3 cells are consistently MHC class II negative and 
cannot be induced to express these molecules [57], they do not 
qualify as APC for the induction of class II-dependent tumor 
immunity. One must therefore assume that the generation of 
CD4 +, tumor-reactive lymphocytes has occurred as a consequence 
of tumor antigen presentation by host APC (indirect presentation) 
(Fig 3). 
The currently accepted view is that endogenous and exogenous 
proteins are processed in two separate cellular compartments and 
are presented in the context of di1ferent types of MHC molecules 
[61]. Whereas pep tides processed from cytoplasmic proteins are 
complexed with class I molecules in a pre-Golgi compartment, 
endocytosed proteins are enzymatically cleaved in endosomes , and 
the resulting peptides become associated with newly synthesized or 
recycling class II molecules in post-Golgi vesicles [61]. 
It now appears that the linkage between a particular antigen­
presentation pathway and a particular species ofMHC molecules is 
less strict than previously thought. Two groups of researchers 
recently demonstrated the successful presentation of exogenous 
antigens in association with MHC class I molecules [62,63]. This 
finding provides the basis for the hypothesis that host APC play a 
critical role not only in the generation of tumor-reactive, MHC 
class II-restricted CD4 + T cells, but also in the sensitization of 
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Figure 3. Possible mechanisms ofT-cell activation in the M-3 model. DC, dendritic cells; NK, natural killer cells. 
CD8+, MHC class I-restricted cytotoxic T lymphocytes. In line 
with this theory is the work by Huang et al [64], who showed that 
bone marrow-derived APC are needed for the induction of tumor­
specific CD8+ cytotoxic T cells by immunization with cytokine­
based cancer vaccines. 
Taken together, these data allow construction of an hypothesis 
for the mechanisms by which 1L-2-transfected tumor cells induce 
T-cell activation. We assume that the subcutaneous injection of 
1L-2-transfected cancer cells leads to inflammatory tissue reactions 
that ultimately result in lethal injury of the cancer cells. Tumor­
associated antigens, released during the destruction of the cytokine­
producing cancer cells, would then be taken up by professional 
APC (dendritic cells, mononuclear phagocytes) and presented to T 
cells of both subsets, presumably in the draining lymph nodes (Fig 
3). The role ofIL-2 in this scenario could be a twofold one in that 
it acts, via specific receptors, to stimulate the tumoricidal activity of 
the cells rejecting the vaccine (i.e., macrophages, granulocytes, and 
natural killer cells) and/or to enhance the tumor antigen-processing 
or -presenting capacity of the APC. 
If further experiments substantiate the importance of host APC as 
initiators of protective tumor immunity, then tumor antigen­
expressing APC could conceivably serve as potent sensitizing tools 
in the adjuvant immunotherapy of cancer. So far, the most potent 
immunostimulatory cells (i.e., dendritic cells) [65] have only been 
available in limited numbers. Dendritic cells naturally occur in 
relatively small numbers only, and procedures used for their 
isolation and purification are tedious, cumbersome, and time 
consuming. Recendy, several groups of investigators have success-
fully used granulocyte-macrophage colony-stimulating factor in 
combination with other cytokines (tumor necrosis factor-a, IL-4) 
to generate sizable numbers of functionally active dendritic cells 
from their hematopoietic precursors ([66,67]; Strunk et ai, submit­
ted). The combination of this new methodology for the generation 
of immunostimulatory dendritic cells with the technology estab­
lished for the detection, molecular characterization, and expression 
of tumor-associated genes/antigens [15-17,20,21,23] should pro­
vide the basis for the development of a successful APC-assisted 
specific immunotherapy of cancer. 
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